Shots:
Thermo Fisher has entered into a definitive agreement to acquire Clario, enhancing its digital & data capabilities in clinical research
As per the deal, Thermo Fisher Scientific will acquire Clario for $8.875B in cash, with an additional $125M due in January 2027 & ~$400M in performance-based earnouts for 2026–2027; closing is expected mid-2026, after…
In an interview with PharmaShots, Lynne Borthwick, EVP and Chief People Officer shared her views on receiving an honor of 2020 Top workplace by Energage. She also shared what this award means to Clario
Shots:
Clario is a great place to work as it helps partners in transforming lives by unlocking better evidence through clinical…
In an interview with PharmaShots, Joyce Suhy, Senior Vice President, Medical Imaging at Clario shares her views on the PET imaging clinical trials & expands its 2018 collaboration with XingImaging for Alzheimer’s disease and other neurodegenerative diseases
Shots:
Clario & XingImaging have expanded the collaboration to provide PET imaging clinical trials for neurodegenerative therapeutics in China. The initial study used Amyvid (florbetapir) PET imaging to…
In an interview with PharmaShots, Joe Eazor, CEO at Clario share his views on the ERT’s merger with Bioclinica to become Clario for clinical trial innovation and evidence
ERT & Bioclinica merged to become Clario, following its Apr 2021 merger agreement & to generate the clinical evidence, empower the patients & transform their lives by providing better evidence
Clario combines Bioclinica's expertise in imaging,…

